Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 7/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873018 | 0.94 | GRM4 (0.40) | CYP2C9KDM5APIM1HCRTR1HCRTR2 | |
| SCHEMBL5873063 | 0.92 | PIM1 (0.40) | KDM5APIM1 | |
| SCHEMBL5873046 | 0.91 | CYP2C9 (0.43) | CYP2C9KDM5ASMYD2PIM1HRH3 | |
| SCHEMBL5872868 | 0.90 | CYP2C9 (0.40) | CYP2C9KDM5ASMYD2PIM1HCRTR1 | |
| SCHEMBL5775804 | 0.89 | PIM1 (0.38) | CYP2C9KDM5APIM1HCRTR1HCRTR2 | |
| SCHEMBL5769465 | 0.88 | CYP3A4 (0.38) | CYP2C9KDM5APIM1HCRTR1HCRTR2 | |
| SCHEMBL5873198 | 0.87 | KDM5A (0.40) | KDM5APIM1HRH3HCRTR1HCRTR2 | |
| SCHEMBL5873211 | 0.86 | CYP2C9 (0.48) | CYP2C9KDM5ASMYD2PIM1HRH3 | |
| SCHEMBL5873087 | 0.86 | KDM5A (0.39) | KDM5APIM1HCRTR1HCRTR2 | |
| SCHEMBL5872806 | 0.86 | DYRK1A (0.41) | KDM5APIM1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP2C9 695/4885KDM5A 2543/4885SMYD2 2519/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP2C9 695/4885KDM5A 2543/4885SMYD2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.